Secukinumab demonstrates improvements in absolute and relative psoriasis area severity indices in moderate-to-severe plaque psoriasis: results from a European, multicentric, retrospective, real-world study
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Secukinumab demonstrates improvements in absolute and relative psoriasis area severity indices in moderate-to-severe plaque psoriasis: results from a European, multicentric, retrospective, real-world study
Authors
Keywords
-
Journal
JOURNAL OF DERMATOLOGICAL TREATMENT
Volume -, Issue -, Pages 1-8
Publisher
Informa UK Limited
Online
2019-09-27
DOI
10.1080/09546634.2019.1671577
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Secukinumab Drug Survival in Patients with Psoriasis: A multicenter, real-world, retrospective study
- (2019) Tiago Torres et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- A prospective multi-center study assessing effectiveness and safety of secukinumab in a real-life setting in 158 patients
- (2019) José María Ortiz Salvador et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Long‐term continuation with secukinumab in psoriasis: association with patient profile and initial psoriasis clearance
- (2019) L. Ferrières et al. CLINICAL AND EXPERIMENTAL DERMATOLOGY
- Effectiveness and safety of secukinumab in Italian patients with psoriasis: an 84 week, multicenter, retrospective real-world study
- (2019) Matteo Megna et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- US real-world effectiveness of secukinumab for the treatment of psoriasis: 6-month analysis from the Corrona Psoriasis Registry
- (2019) Bruce E. Strober et al. JOURNAL OF DERMATOLOGICAL TREATMENT
- Psoriasis treat to target: defining outcomes in psoriasis using data from a real world, population‐based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR )
- (2019) S.K. Mahil et al. BRITISH JOURNAL OF DERMATOLOGY
- Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis
- (2018) A. Egeberg et al. BRITISH JOURNAL OF DERMATOLOGY
- Secukinumab in moderate-to-severe plaque psoriasis: a multi-center, retrospective, real-life study up to 52 weeks observation
- (2018) Marco Galluzzo et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Drug survival of secukinumab for psoriasis in a real-world setting
- (2018) Erica B. Lee et al. JOURNAL OF DERMATOLOGICAL TREATMENT
- Drug survival of secukinumab in real-world plaque psoriasis patients: A 52-week, multicenter, retrospective study
- (2018) Jorge R. Georgakopoulos et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Real-life efficacy and safety of secukinumab: results from a tertiary hospital in Greece
- (2018) A. Tsentemeidou et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study)
- (2018) R. Bissonnette et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis
- (2018) Andrew Blauvelt et al. CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY
- Treatment of patients with plaque psoriasis with secukinumab in a real-life setting: a 52-week, multicenter, retrospective study in Spain
- (2018) Jaime Notario et al. JOURNAL OF DERMATOLOGICAL TREATMENT
- Secukinumab survival and long-term efficacy in patients with plaque psoriasis: real-life data from a tertiary hospital in Greece
- (2018) E. Sotiriou et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Long-term clinical efficacy and safety of secukinumab for Japanese patients with psoriasis: A single-center experience
- (2017) Mami Momose et al. JOURNAL OF DERMATOLOGY
- Absolute PASI and its correlation with DLQI: An ex post analysis of the CLEAR study
- (2017) JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study
- (2017) Andrew Blauvelt et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Secukinumab treatment of moderate to severe plaque psoriasis in routine clinical care: real-life data of prior and concomitant use of psoriasis treatments from the PROSPECT study
- (2017) A. Körber et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Efficacy and safety of secukinumab in treating moderate to severe plaque psoriasis in two real-world Canadian dermatology clinics: a multicenter retrospective study
- (2017) J.R. Georgakopoulos et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Secukinumab: a review of the anti-IL-17A biologic for the treatment of psoriasis
- (2017) Jillian Frieder et al. Therapeutic Advances in Chronic Disease
- Secukinumab: A Review in Psoriatic Arthritis
- (2016) Matt Shirley et al. DRUGS
- Safety of secukinumab in the treatment of psoriasis
- (2016) Andrew Blauvelt Expert Opinion On Drug Safety
- New and Emerging Therapies in Psoriasis
- (2016) Craig L. Leonardi et al. SEMINARS IN CUTANEOUS MEDICINE AND SURGERY
- Secukinumab: A Review in Moderate to Severe Plaque Psoriasis
- (2015) Karly P. Garnock-Jones AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
- Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: results from the PHOENIX 2 study through 5 years of follow-up
- (2015) R.G. Langley et al. BRITISH JOURNAL OF DERMATOLOGY
- Secukinumab for treating plaque psoriasis
- (2015) Brooke Rothstein et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials
- (2014) Richard G. Langley et al. NEW ENGLAND JOURNAL OF MEDICINE
- One-year safety and efficacy of ustekinumab and results of dose adjustment after switching from inadequate methotrexate treatment: the TRANSIT randomized trial in moderate-to-severe plaque psoriasis
- (2013) K. Reich et al. BRITISH JOURNAL OF DERMATOLOGY
- Risk of Serious Adverse Events Associated With Biologic and Nonbiologic Psoriasis Systemic Therapy
- (2012) Gregorio Carretero ARCHIVES OF DERMATOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started